VolitionRX Limited (VNRX)

[rodman]

VNRX to ring the DJ opening bell Wednesday AM. Watch for news of partner capital infusion arrangements. We will run!!!!!

Blood-based tests are the future of Cancer diagnostics

Blood-based tests are the future of cancer diagnostics as they are non-invasive, less expensive, have high compliance rates, and provide accurate results using novel blood biomarkers. However, there are only a handful of blood tests for cancers – the only blood test commonly used is PSA prostate cancer blood test which has high compliance (around 80%) with 72% sensitivity and the recently launched CRC test (EpiGenomics Epi proColon(R)) in Europe with 68% accuracy. We believe companies that are focused on blood-based tests such as VNRX are at a distinct competitive advantage and are well positioned to capture this large unmet medical need.

Initiate coverage with a price target of $6.70

Our analysis indicates a fair value estimate of $6.70 per share, implying an upside of 64.1% from the recent price of $4.15. We view VNRX as a high-risk/high-reward investment opportunity in the healthcare biopharmaceutical space
Set an entrance price 3.90 if you can get it?